NEUP
Neuphoria Therapeutics Inc. Common StockNEUP
NEUP
About: Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
Employees: 24
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
242% more capital invested
Capital invested by funds: $273K [Q4 2024] → $935K (+$662K) [Q1 2025]
9.27% more ownership
Funds ownership: 0% [Q4 2024] → 9.27% (+9.27%) [Q1 2025]
13% less funds holding
Funds holding: 8 [Q4 2024] → 7 (-1) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for NEUP.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced an upcoming presentation at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting.
Neutral
GlobeNewsWire
3 weeks ago
Neuphoria Provides First Quarter 2025 Business Updates
BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provides business updates for the First Quarter of 2025.
Neutral
GlobeNewsWire
2 months ago
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company's pipeline diversification beyond BNC210 US $15M milestone payment from Merck extends company's cash runway to Q3 2026 Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder (SAD) is progressing as planned with topline readout anticipated in Q3 2025 A Phase 2b dose ranging study with a lower dose of BNC210 in post-traumatic stress disorder (PTSD) is planned to follow the read-out of the Phase 3 study in social anxiety disorder SAD. BURLINGTON, Mass.
Neutral
GlobeNewsWire
3 months ago
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients' lives, announced today that it will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York City on Monday, March 3rd, 2025.
Neutral
GlobeNewsWire
4 months ago
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator
Positive
Zacks Investment Research
4 months ago
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Neuphoria Therapeutics Inc. (NEUP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Neutral
GlobeNewsWire
5 months ago
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited's proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time).
Charts implemented using Lightweight Charts™